This two-day course is your comprehensive guide to radioembolization. Dive into the latest data and techniques by reviewing slides from our expert faculty:

Thursday, 6 June: Data and Discussion 

Session 1 - Fundamentals (100)

1.1 What Do I Need to Know as an IR in Oncology, presented by Daniel B. Brown, MD, FSIR, Vanderbilt University Medical Center

1.2 Principles of Glass and Resin Microspheres 

1.3 Absorbed Dose and Specific Activity

1.4 Optimizing Patient Selection: HCC vs Metastatic Disease

1.5 Patient Management: Clinical and Imaging

Session 2 - Data Deep Dive: Early Stage HCC (100-200)

2.1 Why I Choose Glass Microspheres for RadSeg

2.2 Why I Choose Resin Microspheres for RadSeg

2.3 Is TARE Superior in Bridging/Downstaging Patients?

2.4 Role of Radiation Lobectomy in HCC

Session 3 - Data Deep Dive: Intermediate & Advanced HCC (100-200)

3.1 TARE or TACE in Intermediate Stage HCC?

3.2 Expanding Role for Systemic Therapy in HCC: Moving to Intermediate Stage and Combinations

3.3 Is TARE Still Relevant in Advanced Stage HCC?

3.4 Checkpoint Inhibitor Review for Advanced Stage: Potential for Combination?

Session 4 - Everything Else (100-200)

4.1 mCRC: When to Use TARE Amongst Systemic Therapy

4.2 Cholangiocarcinoma: TARE/SBRT or Systemic

4.3 mNET: Is TARE Making a Comeback?

4.4 Current Status of Data and Ongoing Trials in Glass Microspheres

4.5 Current Status of Data and Ongoing Trials in Resin Microspheres

4.6 Current Status of Data and Ongoing Trials in Radio-opaque Glass Microspheres

Friday, 7 June: Tips, Tricks & Techniques 

Session 5: Logistics (100)

5.1 What You Need to Build a Y90 Practice

5.2 Coding and Reimbursement 

5.3 Volumetry, Prescribing a Dose, and Order for Resin Microspheres

5.4 Volumetry, Prescribing a Dose, and Order for Glass Microspheres

5.5 TARE in Private Practice and OBLs

5.6 Review of NRC Safety Events in Radioembolization

Session 6: Case Studies (200-300)

6.1 Radiation Segmentectomy

6.2 Radiation Lobectomy

6.3 HCC with Portal Vein Invasion

Session 7: Dosimetry Case Studies (200-300

7.1 High Lung Shunt

7.2 Multifocal HCC

7.3 Multifocal mCRC

7.4 Cholangiocarcinoma

Session 8: Technical Challenges in Radioembolization (300)

8.1 Flow Diversion and Angiosome Modulation: Balloons, Coils, Plugs, and Gelfoam

8.2 Radioembolization of Tumors with Extra-hepatic Supply

8.3 When and How to Use Multi-vial, Multi-catheter Delivery

8.4 When Not to Perform TARE

SIO2022 Conference Recordings

This recording is part of the SIO2022 Conference Recordings Bundle. Click here to purchase the full bundle and save!

The second iteration of the SIO Bone Club, hosted during 2023 IO Awareness Week. Faculty review cases and discuss treatment options, device selection and usage, tips and tricks, and lessons learned from their own experiences. This webinar is jointly supported by BD, Boston Scientific, Stryker, and Varian Medical Systems.

Moderators: 

• Sean M. Tutton, MD, FSIR, FCIRSE, SIO Education Advisor, Professor of Radiology and Orthopedics, UC San Diego
• Jack Jennings, MD, PhD, SIO Treasurer, Professor and Chief of Musculoskeletal Radiology, Washington University St. Louis

Faculty: 

• Tony Brown, MD, Interventional Radiologist, Radiology Imaging Associates Endovascular
• Scott J. Genshaft, MD, Interventional and Diagnostic Radiologist, UCLA Health
• Marwan Moussa, MD, Instructor of Radiology, Beth Israel Deaconess Medical Center/Harvard Medical School
• Alan Alper Sag, MD, Assistant Professor of Interventional Radiology and Orthopaedic Surgery, Duke University Medical Center

The Society of Interventional Oncology (SIO) released a 2019 white paper on immunotherapy and interventional oncology (IO) that stated, “The role of immunotherapy in cancer care is rapidly developing, and immunotherapy will continue to be a key player in improving cancer care. As our role as interventional oncologists in relation to immunomodulation continues to take shape, multiple questions and challenges exist for determining some of the optimal approaches and implementing immunotherapy into practice.”⁵ Multidisciplinary management of HCC and other cancers has become a given in medicine. IOs must be cognizant of the rapidly evolving role of immunotherapy in the management of HCC, alone, in combination, and with loco-regional interventional therapies.

 The Society of Interventional Oncology (SIO) is committed to advancing the role of interventional oncology to enhance the traditional pillars of cancer treatment: surgery, radiotherapy, and chemotherapy to deliver personalized treatment plans. Working in multidisciplinary teams, IOs play an important role in determining the best course of treatment. It is essential to ensure that these clinicians are up to date with the latest clinical trial results and ongoing research on advances in HCC therapeutic agents to understand current and potential options throughout the course of the disease. 

This 100-level webinar targets trainees, residents, and other early career physicians who are interested in learning the basics of different Y90 methodologies, how and why to select one treatment method over another, and the step-by-step processes of Y90 treatment from start to finish. Faculty will share case examples from initial clinic visit, mapping, and follow up to illustrate decision making and common pitfalls. Faculty will also discuss new dosimetry software and outlooks on the future of personalize dosimetry.

Learning Objectives

• Define basic processes of different Y90 treatment methodologies
• Evaluate which treatment is the most appropriate selection for different patients
• Examine case examples

SIO2021 Hackathon Winner, Michelle Bardis, MD, PGY1, provides an update on her research (June 2022).

SIO2021 Conference Recordings

This recording is part of the SIO2021 Conference Recordings Bundle. Click here to purchase the full bundle and save!

This recording is part of the SIO2021 Conference Recordings Bundle. Click here to purchase the full bundle and save!